Prediction of left ventricular function in patients after acute myocardial infarction treated with primary angioplasty

Cardiology Journal

Volumn 13, Issue 7, 2006, Pages 605-619

  Światkiewicz, Iwona ^a   Grubecki, Arkadiusz ^a   Białoszyński, Tomasz ^a   Fabiszak, Tomasz ^a   Koziński, Marek ^a   Woźnicki, Marek ^a   Król, Anna ^a   Sukiennik, Adam ^a   Bogdan, Maria ^a   Dobosiewicz, Ryszard ^a   Kochman, Wacław ^a   Chojnicki, Maciej ^a   Grześk, Grzegorz ^a   Sinkiewicz, Władysław ^a   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Echocardiography; Left ventricular systolic and diastolic function; N terminal pro brain natriuretic peptide; Post infarct left ventricle remodelling; Primary percutaneous transluminal coronary angioplasty

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BRAIN NATRIURETIC PEPTIDE; CLOPIDOGREL; CREATINE KINASE; HEPARIN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AMINO TERMINAL SEQUENCE; ANGIOCARDIOGRAPHY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORRELATION ANALYSIS; DISEASE DURATION; ECHOCARDIOGRAPHY; ENZYME ACTIVITY; EPICARDIUM; FEMALE; FOLLOW UP; HEART INFARCTION SIZE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE RELAXATION; HEART SIZE; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RISK REDUCTION; SEQUENCE ANALYSIS; ST SEGMENT ELEVATION; THORAX PAIN; TREATMENT OUTCOME;

EID: 39149092672     PISSN: 18975593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet, 2003; 361: 13-20.
2. Van de Wert F, Ardissino D, Betriu A et al. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J, 2003; 24: 28-66.
3. Ribichini F, Wijns W. Acute myocardial infarction: reperfusion treatment. Heart, 2002; 88: 298-305.
4. Franzosi MG, Santoro E, De Vita C et al. on behalf of the GISSI Investigators. Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute myocardial infarction. Circulation, 1998; 98: 2659-2665.
5. Cohn JN, Ferrari R, Sharpe N. Cardiac remodelling - concepts and clinical implications: a consensus paper from an international forum on cardiac remodelling. On behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol, 2000; 35: 569-582.
6. Bolognese L, Neskovic AN, Parodi G et al. Left ventricular remodelling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications. Circulation, 2002; 106: 2351-2357.
7. Carrabba N, Valenti R, Parodi G, Santoro GM, Antoniucci D. Left ventricular remodeling and heart failure in diabetic patients treated with primary angioplasty for acute myocardial infarction. Circulation, 2004; 110: 1974-1979.
8. Giannuzzi P, Temporelli PL, Bosimini E et al. Heterogenity of left ventricular remodeling after acute myocardial infarction: results of the GISSI-3 Echo Substudy. Am Heart J, 2001; 141: 131-138.
9. Spencer FA, Meyer TE, Goldberg RJ et al. Twenty year trends (1975-1995) in the incidence, in-hospital and long-term death rates associated with heart failure complicating acute myocardial infarction: a community-wide perspective. J Am Coll Cardiol, 1999; 34: 1378-1387.
10. Poulsen SH, Jensen SE, Moller JE et al. Prognostic value of left ventricular diastolic function and association with heart rate variability after a first acute myocardial infarction. Heart, 2001; 86: 376-380.
11. Nijland F, Kamp O, Karreman AJ et al. Prognostic implications of restrictive left ventricular filling in acute myocardial infarction: a serial Doppler echocardiographic study. J Am Coll Cardiol, 1997; 30: 1618-1624.
12. Poulsen SH, Jensen SE, Egstrup K Longitudinal changes and prognostic implication of left ventricular diastolic function in first acute myocardial infarction. Am Heart J, 1999; 137: 910-918.
13. Cerisano G, Bolognese L, Carrabba N et al. Doppler-derived mitral deceleration time: an early strong predictor of left ventricular remodelling after reperfused anterior acute myocardial infarction. Circulation, 1999; 99: 230-236.
14. Agewall S. How should we evaluate an open artery in STEMI patients? Eur Heart J, 2005; 26: 634-636.
15. Solomon A, Gersh B. The open-artery hypothesis. Annu Rev Med, 1998; 49: 63-76.
16. Roe MT, Ohman EM, Maas ACP et al. Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion. J Am Coll Cardiol, 2001; 37: 9-18.
17. Bolognese L, Carrabba N, Parodi G et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation, 2004; 109: 1121-1126.
18. Zijlstra F, Hoorntje JC, de Boer MJ et al. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med, 1999; 341: 1413-1419.
19. Weaver WD, Simes RJ, Betriu A et al. Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review. JAMA, 1997; 278: 2093-2098.
20. Widimsky P, Budesinsky T, Vorac D et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction: Final results of the randomized national multicentre trial - PRAGUE-2. Eur Heart J, 2003; 24: 94-104.
21. Zaman AG, Helft G, Worthley SG et al. Ventricular dilatation after anterior ST-elevation myocardial infarction in the thrombolytic era. Am Heart J, 2000; 140: 611-616.
22. Iwakura K, Ito H, Kawano S et al. Assessing myocardial perfusion with the transthoracic Doppler technique in patients with reperfused anterior myocardial infarction: comparison with angiographic, enzymatic and electrocardiographic indices. Eur Heart J, 2004; 25: 1526-1533.
23. Topol EJ Current status and future prospects for acute myocardial infarction therapy. Circulation, 2003; 108: III-6-III-13.
24. Bolognese L, Antoniucci D, Rovai D et al. Myocardial contrast echocardiography versus dobutamine echocardiography for predicting functional recovery after acute myocardial infarction treated with primary coronary angioplasty. J Am Coll Cardiol, 1996; 28: 1677-1683.
25. Ito H, Maruyama A, Iwakura K et al. Clinical implications of the 'no-reflow' phenomenon. A predictor of complications and left ventricular remodeling in reperfused anterior wall myocardial infarction. Circulation, 1996; 93: 223-228.
26. Gibson CM, Murphy SA, Rizzo MJ et al. Relationship between TIMI frame count and clinical outcomes after thrombolytic administration. Thrombolysis in Myocardial Infarction (TIMI) Study Group. Circulation, 1999; 99: 1945-1950.
27. Petronio AS, Rovai D, Musumeci G et al. Effects of abciximab on microvascular integrity and left ventricular functional recovery in patients with acute infarction treated by primary coronary angioplasty. Eur Heart J, 2003; 24: 67-76.
28. Wita K, Filipecki A, Weglarz P et al. Przewidywanie niekorzystnej przebudowy lewej komory u chorych z ostrym zawałem mieśnia sercowego leczonych pierwotna przezskórna interwencja wieńcowa (przewidywanie remodelingu lewej komory). Post Kardiol Interw, 2005; 1: 86-96.
29. Kamp O, Lepper W, Vanoverschelde J et al. Serial evaluation of perfusion defects in patients with a first acute myocardial infarction referred for primary PTCA using intravenous myocardial contrast echocardiography, Eur Heart J, 2001; 22: 1485-1495.
30. Doust JA, Pietrzak E, Dobson A, Glasziou P. How well does B-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ, 2005; 330: 625.
31. Silver MA, Maisel A, Yancy CW et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognosis, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail, 2004; 10 (5 suppl 3): 1-30.
32. Crilley JG, Farrer M. Left ventricular remodeling and brain natriuretic peptide after first myocardial infarction. Heart, 2001; 86: 638-642.
33. Richards AM, Nicholls MG, Yandle TG et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. The Christchurch Cardioendocrine Research Group. Heart, 1999; 81: 114-120.
34. Omland T, Aakvaag A, Bonarjee VV et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and an-terminal proatrial natriuretic peptide. Circulation, 1996; 93: 1963-1969.
35. de Lemos JA, Morrow DA, Bentley JH et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med, 2001; 345: 1014-1021.
36. de Lemos JA, Morrow DA Brain natriuretic peptide measurement in acute coronary syndromes: ready for clinical application? Circulation, 2002; 106: 2868-2874.
37. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol, 2002; 40: 437-445.
38. Omland T, Persson A, Ng L et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation, 2002; 106: 2913-2918.
39. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med, 1997; 336: 1621-1628.
40. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med, 1993; 329: 1615-1622.
41. Nagaya N, Nishikimi T, Goto Y et al. Plasma brain natriuretic peptide is a biochemical marker for prediction of progressive ventricular remodelling after acute myocardial infarction. Am Heart J, 1998; 135: 21-28.
42. Katayama T, Nakashima H, Furudono S, Honda Y, Suzuki S, Yano K. Predictive factors of deteriorating left ventricular function a direct percutaneous coronary intervention for acute anterior myocardial infarction. J Cardiol, 2004; 43: 205-213.
43. Richards AM, Nicholls MG, Espiner EA et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation, 2003; 107: 2786-2792.
44. Terkelsen CJ, Lassen JF, Norgaard BL et al. Reduction of treatment delay in patients with ST-elevation myocardial infarction: impact of pre-hospital diagnosis and direct referral to primary percutanous coronary intervention. Eur Heart J, 2005; 26: 770-777.
45. Andersen H, Nielsen T, Vesterhund T et al. Danish multicenter randomized study on fibrinolytic therapy versus acute coronary angioplasty in acute myocardial infarction: rationale and design of the DANish trial in Acute Myocardial Infarction-2 (DANAMI-2). Am Heart J, 2003, 146, 234-241.
46. Brodie BR, Stuckey TD, Kissling G, Hansen CJ, Weintraub RA, Kelly TA. Importance of infarct-related artery patency for recovery of left ventricular function and late survival after primary angioplasty for acute myocardial infarction. J Am Coll Cardiol, 1996; 28: 319-325.
47. Sheiban I, Fragasso G, Lu C, Tonni S, Trevi GP, Chierchia SL. Influence of treatment delay on long-term left ventricular function in patients with acute myocardial infarction successfully treated with primary angioplasty. Am Heart J, 2001; 141: 603-609.
48. Zijlstra F, Patel A, Jones M et al. Clinical characteristics and outcome of patients with early (< 2 h), intermediate (2-4 h) and late (> 4 h) presentation treated by primary coronary angioplasty or thrombolytic therapy for acute myocardial infarction. Eur Heart J, 2002; 23: 550-557.
49. Araszkiewicz A, Lesiak M, Grajek S et al. Czy opóźnienie terapii wpływa na skuteczność reperfuzji oraz funkcje lewej komory u chorych z zawałem serca ściany przedniej leczonych pierwotna angioplastyka wiehcowa? Pol Arch Med Wewn, 2004; 112: 1407-1413.
50. Stone GW, Grines CL, Browne KF et al. Predictors of in-hospital and 6-month outcome after acute myocardial infarction in the reperfusion era: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. J Am. Coll Cardiol, 1995; 25: 370-377.
51. Stone GW, Grines CL, O'Neill WW. Primary coronary angioplasty versus thrombolysis. N Engl J Med, 1997; 337: 1168-1169.
52. Baks T, van Geuns RJ, Biagini E et al. Recovery of left ventricular function after primary angioplasty for acute myocardial infarction. Eur Heart J, 2005; 26: 1070-1077.
53. Schöming A, Kastrati A, Dirschinger J et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl J Med, 2000; 343: 385-391.
54. Gibson CM, de Lemos JA, Antman EM; TIMI Study Group. Time is muscle in primary PCI: the strength of the evidence grows. Eur Heart J, 2004; 25: 1001-1002.
55. Agati L, Iacoboni C, De Maio F et al. Tissue level perfusion after primary or rescue coronary angioplasty in acute myocardial infarction. A myocardial contrast echocardiography study. J Am Coll Cardiol, 2003; 41: 434A.
56. Antoniucci D, Valenti R, Migliorini A et al. Relation of time to treatment and mortality in patients with acute myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol, 2002; 89: 1248-1252.
57. De Luca G, van't Hof A, de Boer M et al. Time-to treatment significantly affects the extent of ST-segment resolution and myocardial blush in patients with acute myocardial infarction treated by primary angioplasty. Eur Heart J, 2004; 25: 1009-1013.
58. Suzuki S, Yoshimura M, Nakayama M et al. Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation, 2004; 110: 1387-1391.
59. Nagaya N, Goto Y, Nishikimi T et al. Sustained elevation of plasma brain natriuretic factor levels associated with progressive ventricular remodelling after acute myocardial infarction. Clin Sci (London), 1999, 96: 129-136.
60. Talwar S, Squire I, Downie P et al. Profile of plasma N-terminal proBNP following acute myocardial infarction; correlation with left ventricular systolic dysfunction. Eur Heart J, 2000; 21: 1514-1521.
61. Nilsson JC, Groenning BA, Nielsen G et al. Left ventricular remodelling in the first year after acute myocardial infarction and the predictive value of N-terminal pro brain natriuretic peptide. Am Heart J, 2002; 143: 696-702.
62. Katayama T, Nakashima H, Yonekura T et al. Clinical significance of acute-phase brain natriuretic peptide in acute myocardial infarction treated with direct coronary angioplasty. J Cardiol, 2003; 42: 195-200.
63. Mega JL, Morrow DA, De Lemos JA et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-elevation myocardial infarction: an ENTIRE TIMI-23 substudy. J Am Coll Cardiol, 2004; 44: 335-339.
64. Grabowski M, Filipiak K, Karpiński G et al. Serum BNP levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute STEMI treated with primary angioplasty. Am Heart J, 2004; 148: 655-662.
65. Gaszewska-Zurek E, Zurek P, Olszówka P, Kargul T, Woś S, Tendera M Influence of coronary artery bypass grafting performer in patients with unstable angina on left ventricular remodeling in medium-term follow-up. Kardiol Pol, 2005; 63: 115-123.
66. Topol EJ, Yadav JS Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation, 2000; 101: 570-580.
67. Troughton RW, Prior DL, Pereira JJ et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function. J Am Coll Cardiol, 2004; 43: 416-422.
68. Bettencourt P, Ferreira A, Pardal-Oliveira N et al. Clinical significance of brain natriuretic peptide in patients with postmyocardial infarction. Clin Cardiol, 2000; 23: 921-927.
69. Tschope C, Kasner M, Westermann D et al. The role of NT-proBNP in the diagnostics of isolated diastolic dysfunction: correlation with echocardiographic and invasive measurements. Eur Heart J, 2005; 26: 2277-2284.
70. Sabatine MS, Morrow DA, de Lemos JA et al. Multi-marker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation, 2002; 105: 1760-1763.
71. Califf RM Cardiac markers in acute coronary syndromes - refining our knowledge. Eur Heart J, 2003; 24: 136-137.